Skip to content
sellModerate cluster of 310b5-1 plan

Andrew D Dickinson sold $23M of GILD

Chief Financial Officer at GILEAD SCIENCES, INC.. 248,645 shares at an average of $92.76, traded Nov 29, 2024, filed Dec 3, 2024.

Warning score
47
Value
$23M
248,645 shares
Holdings after
138,919
-64% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CFO
    +22
  • Trade size
    $23.1M at market
    +25
  • Share of holdings sold
    Sold 64% of holdings
    +20
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +0.2%, 3m +25.1%, 6m +20.0%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

GILDOct 9, 2026 · close 151.17
Since filing Dec 3, 2024: +72.5%SPY +31.8% · excess +40.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001127602-24-028397, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 29, 2024MOption exercise
Common Stock10b5-1
+18,630$73.77$1.4M157,549Dec 3, 2024
Nov 29, 2024MOption exercise
Common Stock10b5-1
+26,170$57.92$1.5M183,719Dec 3, 2024
Nov 29, 2024MOption exercise
Common Stock10b5-1
+33,660$68.75$2.3M217,379Dec 3, 2024
Nov 29, 2024MOption exercise
Common Stock10b5-1
+60,885$71.91$4.4M278,264Dec 3, 2024
Nov 29, 2024MOption exercise
Common Stock10b5-1
+43,340$72.70$3.2M321,604Dec 3, 2024
Nov 29, 2024MOption exercise
Common Stock10b5-1
+65,960$72.70$4.8M387,564Dec 3, 2024
Nov 29, 2024SOpen-market sale
Common Stock10b5-1
-120,715$92.77$11M266,849Dec 3, 2024
Nov 29, 2024SOpen-market sale
Common Stock10b5-1
-127,930$92.76$12M138,919Dec 3, 2024
Nov 29, 2024MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-26,170$0.00$0130,860Dec 3, 2024
Nov 29, 2024MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-18,630$0.00$00Dec 3, 2024
Nov 29, 2024MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-33,660$0.00$00Dec 3, 2024
Nov 29, 2024MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-60,885$0.00$00Dec 3, 2024
Nov 29, 2024MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-43,340$0.00$00Dec 3, 2024
Nov 29, 2024MOption exercise
Non-qualified Stock Option (Right to Buy)derivative10b5-1
-65,960$0.00$00Dec 3, 2024

Related signals

Other insiders at GILEAD SCIENCES, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
GILDsell10b5-1
GILEAD SCIENCES, INC.
Daniel Patrick O'Day
Chairman & CEO
$2.2M
15,000 shares
-3%
34Weak
GILDsell 310b5-1
GILEAD SCIENCES, INC.
Andrew D Dickinson
Chief Financial Officer
$436k
3,000 shares
-2%
27Weak
GILDsell 310b5-1
GILEAD SCIENCES, INC.
Johanna Mercier
Chief Comm & Corp Aff Officer
$433k
3,000 shares
-3%
45Moderate
GILDsell 510b5-1
GILEAD SCIENCES, INC.
Daniel Patrick O'Day
Chairman & CEO
$2.2M
15,000 shares
-3%
40Moderate
GILDsell 510b5-1
GILEAD SCIENCES, INC.
Anthony Welters
director
$2.7M
18,000 shares
-87%
26Weak
GILDsell 510b5-1
GILEAD SCIENCES, INC.
Jeffrey Bluestone
director
$725k
5,000 shares
-45%
33Weak
GILDsell 510b5-1
GILEAD SCIENCES, INC.
Andrew D Dickinson
Chief Financial Officer
$415k
3,000 shares
-2%
25Weak
GILDsell 510b5-1
GILEAD SCIENCES, INC.
Johanna Mercier
Chief Comm & Corp Aff Officer
$3.9M
28,000 shares
-19%
45Moderate
GILDsell 310b5-1
GILEAD SCIENCES, INC.
Daniel Patrick O'Day
Chairman & CEO
$2.0M
15,000 shares
-2%
33Weak
GILDsell 310b5-1
GILEAD SCIENCES, INC.
Andrew D Dickinson
Chief Financial Officer
$390k
3,000 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Andrew D Dickinson sold $23M of GILD | InsiderTell